Table 2.

The association of socio-demographic characteristics, clinical features, and pharmacological therapy with FMS tender point count.

Feature	Mean (SD) tender point count		p-value
	Feature present	Feature absent
Socio-demographic characteristic
Female	14.9 (4.7)	16.9 (2.3)	0.292
Age
20–39 years	14.9 (5.2)
40–60 years	15.2 (4.4)		0.600
>60 years	14.2 (5.4)
Education (>14 years)	15.0 (4.9)	15.0 (4.6)	0.989
Exercises	15.2 (4.6)	15.0 (4.7)	0.782
Smokes cigarettes	16.6 (3.1)	14.9 (4.7)	0.315
Current clinical feature
Tiredness	15.2 (4.7)	10.4 (2.5)	0.024*
Anorexia	15.8 (4.0)	14.8 (4.8)	0.307
Weight loss	13.9 (5.3)	15.1 (4.6)	0.371
Insomnia	14.8 (5.0)	15.5 (4.0)	0.418
Cognitive dysfunction	15.4 (4.7)	13.4 (4.5)	0.050*
Headache	15.8 (4.0)	12.9 (5.7)	0.001*
Shortness of breath	15.9 (4.7)	13.5 (4.6)	0.003*
Constipation	15.8 (4.0)	13.9 (5.7)	0.001*
Diarrhea	15.9 (4.3)	14.7 (4.8)	0.157
Urinary frequency	16.0 (4.1)	13.8 (5.0)	0.005*
Arthralgia	15.2 (4.5)	10.2 (6.5)	0.009*
Subjective swelling	16.0 (4.6)	14.3 (4.6)	0.029*
Morning stiffness	15.4 (4.7)	13.0 (4.1)	0.035*
Myalgia	15.1 (4.8)	14.1 (3.0)	0.488
Paresthesia	15.7 (4.5)	12.2 (4.5)	0.001*
Sicca symptoms	16.0 (4.3)	12.7 (4.7)	0.000*
Dysmenorrhea	16.9 (2.7)	12.5 (5.4)	0.000*
Current pharmacological therapy
Tricyclic antidepressants	15.3 (4.2)	14.8 (4.8)	0.546
SSRIs	15.1 (4.8)	13.8 (4.5)	0.084
SNRIs	15.5 (4.1)	14.7 (5.0	0.314
Anticonvulsants	15.2 (4.6)	14.9 (4.8)	0.680
Muscle relaxants	15.6 (4.6)	14.8 (5.0)	0.353
NSAIDs	15.1 (4.6)	14.9 (4.8)	0.772

FMS: Fibromyalgia syndrome; SD: Standard deviation; SSRIs: Serotonin selective reuptake inhibitors; SNRIs: Serotonin-norepinephrine reuptake inhibitors; NSAIDs: Non-steroidal anti-inflammatory drugs

^*p-value ≤ 0.05 by one-way ANOVA